ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer
David Planchard(Université Paris-Saclay), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), С. В. Орлов(St Petersburg University), Urban Scheuring(AstraZeneca (United Kingdom)), Ross A. Soo(National University Cancer Institute, Singapore), Sławomir Mańdziuk(Medical University of Lublin), Diego Márquez-Medina(Hospital Universitari Arnau de Vilanova), Sarayut Lucien Geater(Prince of Songkla University), Paul K. Stockman(AstraZeneca (United Kingdom)), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Jürgen R. Fischer, Shunichi Sugawara(Sendai Kousei Hospital), Yuichiro Takeda(National Center for Global Health and Medicine), Michael McCleod(Sarah Cannon), R. May(AstraZeneca (United States)), Silvia Novello(University of Turin), Mark Powell(Dana-Farber Cancer Institute), K. Park
Cited by 164
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k